Effect of norethisterone and levonorgestrel in low-dose multiphasic oral contraceptives on serum lipids

References

• Stadel B V. Oral contraceptives and cardiovascular disease. N Engl J Med 1981; 305: 420–4
   Google Scholar
• Kay C R. Progestogens and arterial disease-Evidence from the Royal College of General Practitioners' study. Am J Obstet Gynecol 1982; 142: 762–5
   PubMed Web of Science ®Google Scholar
• Layde P M, Beral V, Kay C R. Further analysis of mortality in oral contraceptive users: Royal College of General Practitioners' Oral Contraceptive Study. Lancet 1985; 1: 541–6
   Google Scholar
• Bottinger L E, Boman G, Eklund G, Westerholm B. Oral contraceptives and thromboembolic disease: Effects of lowering oestrogen content. Lancet 1980; 1: 1097–101
   PubMed Web of Science ®Google Scholar
• Ellis J. Low-dose oral contraceptives: Progestin potency, androgenicity, and atherogenic potential. Clin Ther 1986; 8: 607–18
   PubMed Web of Science ®Google Scholar
• Castelli W P, Garrison R J, Wilson P W, Abbott R D, Kalousdia S, Kannel W B. Incidence of coronary heart disease and lipoprotein cholesterol level levels: the Framingham Study. JAMA 1986; 256: 2835–8
   PubMed Web of Science ®Google Scholar
• Ellis J W. Multiphasic oral contraceptives, efficacy and metabolic impact. J Reprod Med 1987; 32: 28–36
   Google Scholar
• Policar M. Clinical Experience with Multiphasic Oral Contraceptives. J Reprod Med 1986; 31: 939–45
   Google Scholar
• Lie R F, Schmitz J M, Pierre K J, Gochman N. Cholesterol oxidasebased determination, by continuous-flow analysis, of total and free cholesterol in serum. Clin Chem 1976; 22: 1627–30
   PubMed Web of Science ®Google Scholar
• Bucholo G, David H. Quantitative determination of serum triglycerides by use of enzymes. Clin Chem 1973; 19(5)476–82
   Google Scholar
• Finley P R, Schifman R B, Williams R J, Lichti D A. Cholesterol in high density lipoprotein: Use of Mg++ /Dextran Sulphate in its enzymatic determination. Clin Chem 1976; 24: 931–3
   Google Scholar
• Siedel J, Hagele E O, Ziegenhorn J, Wahlefeld A W. Reagent for the enzymeatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983; 29: 1075–80
   PubMed Web of Science ®Google Scholar
• Riepponen P, Marniemi J, Rautaoja T. Immunoturbidimetric determination of apolipoprotein A-1 and B in serum. Scand J Clin Lab Invest 1987; 47: 739–44
   PubMed Web of Science ®Google Scholar
• Lewis B. Relation of high-density lipoproteins to coronary artery disease. Am J Cardiology 1983; 52: 5B–8B
   Google Scholar
• Gordon T, Castelli W P, Njortland M. HDL as a protective factor against CDH-The Framingham Study. Am J Med 1977; 62: 707–14
   PubMed Web of Science ®Google Scholar
• Zimmer F, Riebeling V, Benke B, Schuster J, Roskamm H. The LDL-HDL ratio in patients with coronary arteriosclerosis. Z Kardiol 1980; 69: 149–53
   Google Scholar
• Scottolini A G, Bhagavan N P, Oshiro T H, Abe S Y. Serum high-density lipoprotein cholesterol concentrations in hypoand hyperthyroidism. Clin Chem 1980; 26: 584–7
   PubMed Web of Science ®Google Scholar
• Knopp R H, Walden C E, Wahl P W, Hoover J J, Warnick G R, Albers J J, Ogilvie J T, Hazzard W R. Oral Contraception and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: Relationships to estrogen and progestin potency. J Clin Endocrinol Metab 1981; 53: 1123–32
   PubMed Web of Science ®Google Scholar
• Knopp R H, Walden C E, Wahl P W, Hoover J J. Effects of oral contraceptives on lipoprotein triglyceride and cholesterol: Relationships to estrogen and progestin potency. Am J Obstet Gynecol 1982; 142: 725–31
   PubMed Web of Science ®Google Scholar
• Powell M G, Hedlin A M, Cerskus I, Kakis G, Prudham D, Rosenrot P. Effects of oral contraceptives on lipoprotein lipids: A prospective study. Obstet Gynecol 1984; 63: 764–70
   Google Scholar
• Lipson A, Story D B, LaRosa J C, Muesing R A, Cleary P A, Miller V T, Gilbert P R, Stadel B. Progestins and oral contraceptive-induced lipoprotein changes: A prospective study. Contraception 1986; 34: 121–34
   PubMed Web of Science ®Google Scholar
• Burkman R T, Robinson J C, Kruszon-Moran D, Kimball A W, Kwiterovich P, Burford R G. Lipid and lipoprotein changes associated with oral contraceptive use: A randomized clinical trial. Obstet Gynecol 1988; 71: 33–8
   PubMed Web of Science ®Google Scholar
• Patsch W, Brown S A, Gotto A M, Young R L. The effect of triphasic oral contraceptives on plasma lipids and lipoproteins. Am J Obstet Gynecol 1989; 161: 1396–401
   Google Scholar
• Godsland I F, Crook D, Simpson R, Proudler T, Felton C, Lees B, Anyaoku V, Devenport M, Wynn V. The effect of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990; 323: 1375–81
   PubMed Web of Science ®Google Scholar
• Castelli W P. Cardiovascular disease in women. Am J Obstet Gynecol 1988; 158: 1553–60
   PubMed Web of Science ®Google Scholar
• Burkman R T. Lipid and lipoprotein changes in relation to oral contraception and hormone replacement therapy. Fertil and Steril 1988; 49: 39S–50S
   PubMed Web of Science ®Google Scholar